https://www.neurologylive.com/view/phase-2-3-results-zavegepant-showcase-effectiveness-as-acute-migraine-medication
Evidence of therapeutic benefit for zavegepant was observed on multiple secondary end points, including return to normal function at 30 min postdose, sustained pain relief, and sustained pain freedom.
Create an account or login to join the discussion